The Safety and Clinical Effectiveness of Denosumab Among Chinese Men With Osteoporosis – a Real World Study in Taiwan (20210040)

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS45083
• Study ID:
  47635
• Official title and acronym:
  The Safety and Clinical Effectiveness of Denosumab Among Chinese Men With Osteoporosis – a Real World Study in Taiwan (20210040)
• DARWIN EU® study:
  No
• Study countries:
  Taiwan
• Study description:
  No information provided.
• Study status:
  Finalised

Research institutions and networks

Institutions

Amgen

United States

Study timelines

Date when funding contract was signed

Planned:18/10/2021

Actual:18/10/2021

Study start date

Planned:14/01/2022

Actual:18/01/2022

Data analysis start date

Planned:14/01/2022

Actual:18/01/2022

Date of final study report

Planned:14/01/2023

Actual:22/04/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable